Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 12/20 | 1.00 |
| ▸ | PKLR | P30613 | 6/20 | 1.00 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18134604 | 0.86 | MCOLN3 (0.83) | PKMPKLRMCOLN3TSHRMEN1 | |
| SCHEMBL19871301 | 0.82 | PKM (0.79) | PKMPKLRTDP1LMNA | |
| SCHEMBL2239830 | 0.81 | PKM (1.00) | PKMPKLRTDP1 | |
| SCHEMBL3169939 | 0.80 | MCOLN3 (0.97) | PKMPKLRMCOLN3TSHRMEN1 | |
| SCHEMBL1725480 | 0.79 | PKM (1.00) | PKMPKLRTDP1LMNA | |
| SCHEMBL3215041 | 0.79 | PKM (0.65) | PKMPKLRMCOLN3TSHRMEN1 | |
| SCHEMBL15014129 | 0.79 | PKM (0.89) | PKMPKLRMCOLN3TSHRMEN1 | |
| SCHEMBL3814970 | 0.79 | MCOLN3 (1.00) | PKMPKLRMCOLN3TSHRMEN1 | |
| SCHEMBL30821997 | 0.79 | MCOLN3 (1.00) | PKMPKLRMCOLN3TSHRMEN1 | |
| SCHEMBL15746499 | 0.78 | PKM (1.00) | PKMPKLRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3372230-B1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS INC (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-3372230-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | Agios Pharmaceuticals, Inc. (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-2704719-B1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS INC (US) | 2018-02-21 | — | — | EP | disclosed |
| US-9707230-B2 | Activators of human pyruvate kinase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-07-18 | — | — | US | disclosed |
| EP-3173415-A2 | ACTIVATORS OF HUMAN PYRUVATE KINASE | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2344453-B1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | US HEALTH (US) | 2016-12-28 | — | — | EP | disclosed |
| US-9403792-B2 | Methods of using pyruvate kinase activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160199370-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2016-07-14 | — | — | US | disclosed |
| US-9290512-B2 | Activators of human pyruvate kinase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150105395-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | US HEALTH (US) | 2015-04-16 | — | — | US | disclosed |
| US-8937067-B2 | Activators of human pyruvate kinase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-01-20 | — | — | US | disclosed |
| US-8841305-B2 | Activators of the human pyruvate kinase M2 receptor | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140148444-A1 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-05-29 | — | — | US | disclosed |
| EP-2704719-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | Agios Pharmaceuticals, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012151450-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20120245141-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2012-09-27 | — | — | US | disclosed |
| US-20110195958-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | US Dept. of Health and Human Services (US) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105395-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PDK4 | PKM 4/4885PKLR 6/4885MCOLN3 4515/4885 |
| US-20140148444-A1 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | PCK1, PDK2, PCK2 | PKM 14/4885PKLR 26/4885MCOLN3 3751/4885 |
| US-20110195958-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PDK4 | PKM 5/4885PKLR 7/4885MCOLN3 3849/4885 |
| US-20160199370-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PDK4 | PKM 4/4885PKLR 7/4885MCOLN3 4568/4885 |
| US-20120245141-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PDK4 | PKM 4/4885PKLR 7/4885MCOLN3 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.